2024-09-08 - Analysis Report
## Gilead Sciences, Inc. (GILD) Stock Analysis Report

**Company Overview:** Gilead Sciences is a biopharmaceutical company that develops and commercializes treatments for life-threatening diseases, including HIV/AIDS, hepatitis B and C, and cancer.

**Performance Analysis:**

**1. Relative Performance:**

* **Cumulative Return:**  GILD's cumulative return over the provided period is 14.01%, significantly lagging behind the S&P 500 (VOO) which has returned 81.34%.
* **Relative Strength:** GILD's relative strength compared to the S&P 500 is currently at -67.33%, ranking it in the 22.39% percentile of its historical performance range.

**2. Recent Price Movement:**

* **Closing Price:** $78.72
* **5-day Moving Average:** $79.06
* **20-day Moving Average:** $76.36
* **60-day Moving Average:** $72.74
* **Analysis:** The price is currently above all three moving averages, suggesting a potential short-term upward trend.

**3. Technical Indicators:**

* **RSI:** 81.67, indicating the stock is currently in overbought territory, suggesting potential for a pullback.
* **PPO:** 0.15,  indicating a bullish momentum, but may be weakening given the RSI reading.
* **Delta_Previous_Relative_Divergence:** 1.41, indicating a recent short-term upward trend, however, the RSI overbought territory suggests caution.
* **Expected Return:** 19.61%, representing the potential 5-year return based on current investment.

**4. Recent Earnings & Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 1.29 | 6.95 B$ |
| 2024-05-08 | -3.34 | 6.69 B$ |
| 2023-11-07 | 1.75 | 7.05 B$ |
| 2023-08-04 | 0.84 | 6.60 B$ |
| 2024-08-08 | 0.84 | 6.60 B$ |

* **Analysis:** Gilead's most recent earnings (2024-08-08) reported EPS of $1.29, beating analysts' expectations.  Revenue was also higher than expected, coming in at $6.95 billion.  The company continues to experience some volatility in its earnings, with a negative EPS reported in Q2 2024. This volatility may be due to ongoing challenges in the HIV treatment market. 

**5. Overall Analysis:**

While GILD's recent earnings performance has been positive, the company faces challenges in maintaining its growth trajectory. The stock is currently overbought and has underperformed the S&P 500 significantly. However, the recent positive earnings and upward price trend indicate potential short-term upside. Investors should monitor the company's performance closely, particularly in relation to the HIV market, and consider factors such as the high RSI and relative underperformance before making investment decisions. 

**Disclaimer:** This is not financial advice. Please consult a qualified financial advisor before making any investment decisions. 
